Orthofix(US:OFIX)2025-08-05 12:30Q2 2025 Financial Performance - Pro Forma Net Sales reached $2007 million, a 35% year-over-year increase on a constant currency basis[18, 27, 28] - Non-GAAP Pro Forma Adjusted EBITDA was $206 million, representing 103% of pro forma net sales, compared to $166 million in Q2 2024[18, 30] - Non-GAAP Pro Forma Adjusted Gross Margin improved to 727%, compared to 713% in Q2 2024[18, 30] - Free Cash Flow was $45 million, showing continued positive year-over-year progress[18] Segment Performance - Bone Growth Therapies (BGT) net sales increased by 6% year-over-year[18, 23] - U S Spine Fixation net sales grew by 5% year-over-year, driven by a 7% increase in U S procedure volume[18, 24] - U S Orthopedics net sales saw a significant increase of 28% year-over-year, marking the fourth consecutive quarter of double-digit growth[18] Future Outlook - The company expects to be free cash flow positive for the full year 2025[36] - Full-year 2025 guidance includes Pro Forma Net Sales of $808 million to $816 million and Pro Forma Adjusted EBITDA of $82 million to $86 million[38]